Brief: Elicio Therapeutics Announces First Patient Dosed In The Eli-002 (Amplify-201) Study In Kras-Driven Cancers
06/10/2021 13:31
Oct 6 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
ELI-002
(AMPLIFY-201) STUDY IN KRAS-DRIVEN CANCERS
Source text for Eikon: ID:nGNXbWLL2Z
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)